New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

Know Labs Unveils KnowU: Wearable Non-Invasive CGM Poised to Revolutionize Glucose Monitoring

What You Should Know: – Know Labs (NYSE American: KNW), a leading innovator in non-invasive medical diagnostic technology, today announced the unveiling of its KnowU™,

February 28, 2024

HeartMate 3 Safety Concerns; First Cath Lab Standards for Kids; Single-Shot PFA

Thoratec refuted most of the 4,500-plus reports that its HeartMate 3 left ventricular assist device may have caused or contributed to a patient’s death. (CBS

December 20, 2023

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference 03.06.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz

June 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.